EGFR and neoplasm: Blockade of EGFR and Notch signalling with bispecific antibodies or combined treatment with bispecific antibodies plus talazoparib significantly inhibited drug-induced activation of the Notch2 and Notch3 cleavage (Figure S6A), and also significant decrease the fraction of ALDH+ cells (Figure S6B) in the in vivo treatment of HCC827 and H1648 tumours.